Medication Exposure and Risk of Dementia and Alzheimer’s Disease Authors: Niti Sharma, Seong Soo A. An, Sang Yun Kim Published: 2024 ABSTRACT Alzheimer’s disease (AD), a complex neurodegenerative disease (ND), is the most predominant cause of dementia among the elderly. Generally, elderly people have multiple chronic health conditions, like hypertension, arthritis, diabetes, insomnia, bowel problems, and depression. Although prescribed medications have beneficial therapeutic compositions, some may have side effects that could hinder cognitive function or worsen cognitive decline. Hence, we should evaluate those medications to guarantee their safety. In the present mechanistic review, we discussed frequently used categories of medication (analgesics, anticholinergics, benzodiazepines, proton pump inhibitors, and statins), concerning their possible involvement in increasing AD and dementia risks. This review summarized the results of various observational studies, meta-analyses, randomized case–control studies, and systematic reviews. As the results were contradictory, it was difficult to ascertain the clear associations between medication usage and increased risks of dementia or AD. The blood-based biomarkers (BBMs) offer a low-cost and accessible alternative for early diagnosis of AD. Systematic reviews combined with meta-analysis would be crucial tools for accurately assessing and summarizing the efficacy of health interventions, yet randomized clinical trials have always been the best way to help with clinical care decisions. Thus, an open discussion is necessary to help individuals determine whether the advantages of utilizing medications outweigh the possible drawbacks. 1. Introduction Alzheimer’s disease (AD) is a complex neurodegenerative disease (ND), associated with progressive decline in memory and cognition. AD is defined by distinct alterations in the brain, such as the accumulation of amyloid-beta (Aβ) protein and neurofibrillary tangles (NFTs) of phosphorylated tau (p-tau) proteins, leading to progressive neuronal loss. Nearly 6.9 million elderly in the United States (US) have AD with 0.2 million under 65 years old believed to have early-onset AD (EOAD). This number could increase to 13.8 million by 2060 [1]. Statistically, the healthcare expenditure and long-term care for individuals with AD have increased, reaching a projected total of USD 360 billion in 2024, reflecting a USD 15 billion rise from the previous year [2]. AD is the most common cause of dementia and may contribute to over 60% of the cases [3], followed by vascular dementia (VD), Lewy body dementia (LBD), frontotemporal dementia (FTD), and mixed-type dementia. Dementia is a syndrome marked by a gradual decline in cognitive and functional abilities significant enough to impact daily activities. With the rising life expectancies, the global population of individuals with dementia is predicted to increase. Globally, approximately 57 million individuals are impacted by dementia and this number is expected to increase to 153 million by 2050 [2]. As life expectancy increases due to better healthcare and lifestyle, the global population of individuals aged 65 years or older would increase with numbers set to surpass 1.6 billion by 2050, more than double the 761 million in 2021. The population of individuals 80 years and older will increase at an accelerated rate and is expected to triple by 2050 [4]. Generally, elderly people have multiple chronic health conditions, like hypertension, arthritis, diabetes, obstructive chronic pulmonary disease, insomnia, indigestion, bowel problems, and depression. As a result, they often consume a higher number of both prescription and non-prescription drugs and thus, they are prone to drug–drug interactions that may enhance adverse outcomes, like falls, injury, and delirium. Moreover, the organs responsible for detoxification also become less effective at this age, which may cause drug toxicity. The risk of potentially inappropriate medications (PIMs) administration would increase in polypharmacy. If these medications would affect cognition, their prolonged use could lead to dementia [5]. Recent research indicated that certain drugs, like anticonvulsants and anticholinergic medications, might be linked to a higher likelihood of developing dementia. This suggested that by avoiding these medications, the risk of developing dementia could potentially be reduced. Yet, it will be frequently challenging to determine the factors contributing to cognitive alterations in the elderly using polypharmacy that can independently impact cognitive abilities. It would be crucial to closely monitor the risks of AD and dementia by addressing modifiable risk factors and assessing through various blood-based biomarkers to prevent dementia on a worldwide scale effectively. The presence of extensive healthcare data from large populations, along with advancements in computational power, allowed the systematic investigation into the link between medications and diseases. As a result, several meta-analyses, observational studies, cohort studies, and clinical studies were carried out on several suspicious drugs for increasing AD and dementia risks. Still, a comprehensive review of the studies’ outcomes would be required. Therefore, in this review, we searched and summarized the existing literature and discussed various classes of drugs that have been associated with the risk of dementia and AD. We anticipate that this review will be helpful to clinicians, researchers, and policymakers and assist in best prescribing guidelines for medicines for preventing and treating patients to reduce AD and dementia. 2. Categories of Drugs Linked to Increased Risks of Dementia and AD According to the literature, the use of certain medications, such as analgesics, anticholinergics, and benzodiazepines, could be associated with varying risks for developing AD and other forms of dementia [6,7,8]. On the other hand, PPIs and statins have unclear or varied connections to dementia, with some indications of potential protective effects or minimal risks [9,10]. The elderly (60+ years) tended to have higher usage rates in comparison to young adults due to age-related health conditions and the prevalence of chronic diseases. Table 1 presents the general breakdown of their use, though exact percentages may vary based on country, healthcare system, and population demographics. For a drug to affect brain function, it must reach the brain by crossing the blood–brain barrier (BBB), which depends on several criteria including lipophilicity. Analgesics like ibuprofen and naproxen have low permeability [23], whereas anticholinergics and benzodiazepines show powerful penetration through the BBB for their therapeutic effect [24,25]. Proton pump inhibitors and statins have different levels of permeability, indicating the possibility of both positive and negative effects in brain-related disorders [26,27]. This comprehension is crucial for improving drug development and therapeutic approaches in central nervous system disorders. Brief information on the targets, protein expression, and location of the targets has been provided (Table 2). 2.1. Analgesics Analgesics are drugs employed for the control and therapy of pain. They function by either diminishing inflammations or altering the brain’s processing and perceptions of pain. Significant global use of pain relievers was driven by the common need for managing various types of pains, such as headaches, muscle pain, injuries, chronic pain, and post-operative recovery. The global analgesics market generated USD 91.62 billion in 2024 and is expected to fetch USD 143.65 billion by 2034 [28]. Over-the-counter (OTC) pain relievers, like paracetamol (acetaminophen), ibuprofen, and aspirin, were among the most widely consumed medications with a global market size of USD 28.6 billion in 2022, which is expected to grow USD 40.9 billion by 2032 [29]. Analgesics have been broadly categorized as non-opioid analgesics (acetaminophen and nonsteroidal anti-inflammatory drugs: NSAIDs, e.g., aspirin, diclofenac, ibuprofen), compound analgesics (combination of non-opioid and weak opioids, e.g., co-codamol a combination of paracetamol and codeine), and opioid analgesics (e.g., fentanyl, codeine, tramadol, morphine) (Figure 1). Regular to high doses of non-aspirin traditional NSAIDs could lead to serious adverse effects on the gastrointestinal and cardiovascular systems. Opioids function by stimulating opioid receptors in both the central and peripheral nervous systems, which decreases the activity of neurons, resulting in a decrease in the transmission of pain signals. Opioid pain medications, such as morphine, oxycodone, and tramadol, were frequently prescribed in healthcare environments to manage intense or prolonged pain, particularly for ailments, like cancer or after surgical procedures. A study indicated that 84% of elderly (62–86 years) were on prescription analgesic medications, among which NSAIDs were the most common (77%), followed by paracetamol (41%), and opioids (32%). This status showed a significant usage of painkillers and their quantities in elderly people, underscoring the necessity of overseeing and controlling pain in this population with opioids [11]. Association of Analgesics with Dementia and AD Risk Opioids may cause cognitive decline by affecting various cognitive functions in the mu (μ)- and kappa (κ)-opioid receptor systems. They could impact primarily hippocampal neurons by boosting glutamate release in presynaptic neurons and enhancing the activities of postsynaptic receptors. The presence of opioids in a synapse prevented the blockage of the N-methyl-D-aspartate receptor (NMDAR) by Mg2+ and increased the NMDAR conductance, eventually inducing long-term potentiation (LTP) [30]. Opioids might change the levels of neurotransmitters, which could impact cognitive function [31,32], and have also been reported to reduce neurogenesis [33]. Individuals on opioids or NSAIDs had slightly increased risks of dementia in comparison to those with less frequent usage or none. In a prospective study (n = 194,758) from the UK Biobank, individuals were grouped into different painkiller categories. In comparison to those without NSAIDs, the aspirin, paracetamol, and 2–3 NSAIDs groups had a greater risk of all-cause dementia (ACD) (Hazard ratio [HR]: 1.12, 1.15 and 1.2, respectively, 95% confidence interval [CI]: 1.01–1.24, 1.05–1.27 and 1.08–1.33, p < 0.05 for aspirin and 2–3 NSAIDs, p < 0.01 for paracetamol). The ibuprofen group did not exhibit a noteworthy correlation with the likelihood of ACD, AD, or VD [34]. Frequent use of paracetamol was also linked to an increased chance of developing dementia in older individuals, irrespective of genetic predisposition to the disease [35]. Extended use of aspirin has been associated with gastrointestinal bleeding, which may result in anemia and reduced blood supply to the brain, leading to cognitive decline [36,37]. Aspirin blocks cyclooxygenase-2 (COX-2), an enzyme involved in the synthesis of prostaglandin E2 (PGE2), a neurotransmitter managing synaptic plasticity and memory [38]. Paracetamol is converted to a toxic metabolite named N-acetyl-p-benzoquinoneimine (NAPQI) in the liver, leading to a decrease in glutathione levels and causing oxidative stress in the body [39]. Recently, a population cohort-based study was conducted on 1,261,682 Korean patients suffering from chronic non-cancer pain (CNCP), 21,800 of whom were opioid users [40], which demonstrated the increased risks of dementia (15%), AD (15%), and unspecified dementia (16%) in adults with CNCP on opioids in comparison to the control group. However, no significant association was observed for VD. A nationwide study in Israel discovered that the elderly population (75 to 80 years) on opioid drugs had a 1.39-fold increased likelihood of developing dementia (aHR: 1.39, 95% CI: 1.01–1.92, p < 0.05) in comparison to non-users [41]. In another population-based study of diagnosed participants aged 65 and older with dementia, 42% were on opioid therapy [42]. The nested case–control study on UK Biobank participants with chronic pain and regular analgesic usages indicated increased opioid use in correlation with an escalated risk of dementia (1 to 5 prescriptions: Odds ratio [OR]: 1.21, 95% CI: 1.07–1.37, Wald χ2: 3.02, degrees of freedom (df):1, p: 0.003; 6 to 20: OR: 1.27, 95% CI: 1.08–1.50, Wald χ2: 2.93, df:1, p: 0.003; more than 20: OR: 1.43, 95% CI: 1.23–1.67, Wald χ2: 4.57, df: 1, p < 0.001) [43] (Figure 2). Among participants in the adult with changes in thought (ACT) study, elevated NSAID consumptions were linked to higher chances of being clinically diagnosed with AD dementia (HR: 1.55, 95% CI: 1.07–2.24) [44] and elevated neuritic plaque (NP) scores (Relative risk [RR]: 2.37; 95%, CI 1.24–4.67) [45]. Although opioid use had a slight association with dementia (HR:1.29, 95%; CI: 1.02–1.62), it was not associated with greater neuropathologic changes (higher NP or NFT scores) [46]. Studies concluded that participants with persistent exposures to NSAIDs had a higher likelihood of developing AD (HR:1.57; 95%; CI:1.10–2.23) and dementia (HR:1.66; 95%; CI:1.24–2.24) [44]. In addition, increased NSAID usages were correlated to higher levels of Aβ42 in the middle frontal gyrus (MFG) and superior and middle temporal gyri (SMTG) regions, but not to increased p-tau levels in any of the above areas. On the other hand, increased opioid usage correlated with higher p-tau levels in the MFG specifically, but did not correlate with Aβ42 levels in any brain region in comparison to those with minimal or no opioid usage. Additionally, frequent opioid usage was linked to the decreased grey matter and hippocampal volumes, as well as the increased white matter hyperintensity volumes. The variation in results could be explained by different mechanisms of action of the two drugs [47]. On the other hand, considerable data indicated that NSAID drugs may delay or even stop the development of AD in other studies [48,49,50,51,52]. A meta-analysis of 17 epidemiological studies found a negative association between the use of NSAIDs and AD risk in individuals from eight countries [49]. AD lesions are defined by persistent neuroinflammation that could lead to the destruction of neurons. The anti-inflammatory drugs delay the onset of inflammation, helping delay AD progression. The probable mechanisms involve the activation of the peroxisome proliferator-activated receptor gamma (PPARγ) and inhibition of COX and β-secretase gene promoter activities by NSAIDs [48,53,54], suppressing the formation of amyloid plaques and inflammatory substances. In a systematic review and meta-analysis of observational studies (n = 13,211), the risk for short-term users (<1 month) was 0.95 (0.70–1.29), while the risk for the intermediate-term users (<24 months) was 0.83 (0.65–1.06) and 0.27 (0.13–0.58) for long-term users (>24 months). The combined relative risk among the eight studies with aspirin users was 0.87 (0.70–1.07) [52]. The relative risk (RR) for AD decreased with the increased duration of NSAID usage [RR: 0.40 (>2 years); RR: 0.65 (<2 years)] [50]. In a prospective cohort study [55], no association was found between the use of prescription opioids (HR: 1.29, 95% CI: 1.02–1.62) or NSAIDs (HR: 1.31, 95% CI: 1.07–1.62) and increased risks of cognitive decline or dementia. Individuals who used high doses of opioids did not show a faster decrease in mental performance upon aging [55]. Likewise, in a Finnish nationwide nested case–control study on a Medication use and Alzheimer’s disease (MEDALZ) cohort (n = 70,718), no link was found between opioid use and a higher risk of AD (aOR: 1.00, 95% CI: 0.98–1.03). Extended use of opioids (>365 days: aOR: 1.02, 95% CI: 0.96–1.08) or high cumulative doses (>90 total standardized doses (TSDs): aOR: 1.02, 95% CI: 0.98–1.07) did not increase the risks of AD [56]. Furthermore, no dementia-like pathology was observed in the community-based autopsy cohort (n = 420) for opioids or NSAID users [46]. A recent systematic review and meta-analysis from 16 cohort studies (n = 236,022) revealed a significant link between using NSAIDs and a decreased risk of AD, in comparison to those without using NSAIDs (RR: 0.81, 95% CI: 0.70 –0.94) [57]. The results varied based on the geographical location; a significant association was observed with the European population (RR: 0.72, 95% CI: 0.56–0.92); a modest association with the North American population (RR: 0.87, 95% CI: 0.72–1.06), while no association in the Asian group (RR: 0.87, 95% CI: 0.36–2.10) was observed in the context of reduced risk of AD [57]. Moreover, prolonged use of NSAIDs could lower the risk of developing AD, but do not provide the same protection against VD [58]. A summary of related studies is presented in Table 3. Hence, the above pieces of evidence highlighted the complex relationship between opioid and NSAID usage and cognitive decline, particularly in the context of dementia risks. While opioids may contribute to cognitive impairment through neurobiological mechanisms, NSAIDs appeared to have a protective effect against dementia from extended usage. As far as analgesics were concerned, the reported literature was contradictory and did not provide conclusive evidence for any association between analgesic usage and increased risks of AD/dementia. Further research is required to clarify these associations and comprehend the underlying mechanisms (Figure 3). 2.2. Anticholinergic Drugs Anticholinergics can cross the BBB and block neurotransmitter acetylcholine (ACh) actions at synapses in the central and peripheral nervous systems (CNS and PNS). Based on the target, drugs have been divided into antimuscarinic and antinicotinic agents. Antimuscarinic agents inhibit ACh binding to muscarinic receptors (mAChR) without affecting nicotinic receptors at the neuromuscular junction, while antinicotinic agents target the nicotinic acetylcholine receptors (nAChR). The majority are non-depolarizing skeletal muscle relaxants used in surgery. Medications with anticholinergic activity impacted mAChR mainly. Anticholinergics have a spectrum of therapeutic applications, like antiemetics, anesthetics, antispasmodics, bronchodilators, and mydriatics [59]. Several commonly used anticholinergics are antiallergic (brompheniramine, clemastine), antidepressants (amitriptyline, paroxetine), antispasmodic (atropine, scopolamine); antipsychotics (clozapine, loxapine), antiemetics (prochlorperazine, promethazine), muscle relaxant (cyclobenzaprine, orphenadrine), antimuscarinics (flavoxate, oxybutynin); anti-Parkinson’s (benztropine, trihexyphenidyl), and antiarrhythmic (disopyramide); blood-pressure lowering medicine (beta (β)-blockers like atenolol, metoprolol) (Figure 4). Elderly people with multiple health conditions have been commonly given medications with anticholinergic effects, which are often used to treat various conditions like insomnia, chronic obstructive pulmonary disease (COPD), depression, Parkinson’s disease (PD), allergies, and overactive bladder. Anticholinergic burden (ACB) is the term used to describe the increased risk of medication-related adverse effects caused by the accumulation of higher levels of exposure to one or more anticholinergic medications. The ACB scale has been frequently used to classify anticholinergics. Drugs with ACB scores of 3 (e.g., atropine and flavoxate) had strong anticholinergic properties in comparison to drugs with a score of 2 (moderate; e.g., cyclobenzaprine and loxapine), and 1 (mild; e.g., atenolol and codeine). Typically, 64.3% of older individuals used anticholinergics, while 9.9% used strong anticholinergics [60]. The common side effects of these drugs include confusion and memory loss, especially in the elderly [61]. Association of Anticholinergics with Dementia and AD Risk Anticholinergic drugs may cause short-term cognitive side effects [61,62] and it was generally believed that cognitive impairment could be reversed by stopping the medication [63]. Nonetheless, multiple reports indicated that anticholinergic drugs could potentially lead to a higher likelihood of long-term cognitive issues [64,65,66]. To ascertain whether prolonged usages of these medications were associated with a higher risk of developing dementia, several studies were conducted as follows [64]. In a German cohort study, 2605 elderly (age > 75 years) without dementia were followed for 4.5 years after starting anticholinergic drugs, revealing a doubled risk of developing dementia (HR: 2.08; 95%). There was a substantially higher risk of developing dementia (HR:1.54) and AD (HR: 1.63) in patients with the greatest anticholinergic burden in comparison to those not taking such medication [7]. Several observational studies were conducted to prove a relationship between anticholinergics and dementia risks [67,68,69]. In a nested case–control study of 58,769 patients, Coupland et al. [70] discovered a higher risk of dementia linked to the cumulative use of anticholinergic medication in a large (284,343 case patients and matched controls) nested case–control study. The antidepressants (aOR: 1.29; 95% CI: 1.24–1.34), bladder antimuscarinics (aOR: 1.65; 95% CI: 1.56–1.75), antipsychotics (aOR: 1.70; 95% CI: 1.53–1.90), antiepileptic (aOR: 1.39; 95% CI: 1.22–1.57), and anti-Parkinson’s drugs (aOR: 1.52; 95% CI: 1.16–2.00) revealed the most significant associations (Figure 5). Antihistamines, antiarrhythmics, antimuscarinic bronchodilators, skeletal muscle relaxants, and gastrointestinal antispasmodics did not show any noteworthy increases in risk factors in the study. Similarly, Richardson and colleagues [67] also discovered higher risks of developing dementia in individuals taking antidepressant, urological, and anti-Parkinson’s medications, while no link was found for gastrointestinal or antihistamine drugs. Stronger associations were also found in individuals diagnosed with VD before the age of 80 rather than AD, suggesting that the mechanism of anticholinergic action might affect vascular and inflammatory pathways along with inhibiting cholinergic actions [70]. Zheng and coworkers pooled fourteen longitudinal and case–control studies of 1,564,181 participants. They concluded that the use of anticholinergics was linked to a higher risk (1.2 folds) of developing ACD and AD [71]. In a population-based study (n = 750; age > 65), individuals taking anticholinergics had a higher probability of cognitive impairment in comparison to non-users (OR: 3.18; 95% CI: 1.93–5.23; p < 0.001) [72]. A cohort study in three French cities revealed a 1.4 to 2.0-fold dementia risk in anticholinergic users in comparison to the non-users [66]. The increased risks of dementia were linked to both low and high anticholinergic drug burdens (ACBs). The anticholinergics seemed to pose a greater risk of cognitive decline, which was accelerated with the changes in AD biomarkers [73]. Taylor-Rowan et al. assessed the risk factor of high anticholinergic burden in elders with no known cognitive issues, who may have experienced a significant rise in their risk of cognitive decline or dementia, potentially up to 227% [74]. Compared to other antidepressants, paroxetine was associated with the highest risk of dementia and AD [75]. Among the anticholinergic drugs, the dementia risk was pronounced with the usage of anti-Parkinson’s, urological, and antidepressant medications [63,71,76,77]; yet, cardiovascular and gastrointestinal medications may offer some level of protection [71]. Additionally, the risk of dementia and AD was directly proportional to the dosage of anticholinergics used (1.6, 2.1, 2.6, and 2.6 times increased risk with one, two, three, and four anticholinergic drugs) [78]. Among the antidepressants, clomipramine, trimipramine, imipramine, amitriptyline, doxepin maprotiline, and tranylcypromine were linked to a higher likelihood of developing dementia in a 12-year follow-up study [79]. Anticholinergic drugs do not just hinder cognitive function by reducing ACh neurotransmission, they also speed up neurodegeneration by inhibiting an ACh-dependent anti-inflammatory system [80]. On the contrary, no significant association between anticholinergics and dementia risk (HR: 1.043; 95% CI: 0.958–1.212, p: 0.139) was observed in a nationwide 15-year follow-up study in Taiwan. However, male patients, age group 65 to over 80 years, long anticholinergic treatment (≥4 years), and high ACB were associated with dementia risk [81]. Low et al. found no significant effect of anticholinergics on cognitive decline in persons in their early to mid-60s [82]. There was no significant difference in the likelihood of developing dementia between users and non-users during an 8-year monitoring period in a French cohort study [65]. The beta-blocker therapy also did not show a higher chance of developing ACD, AD, or mixed dementia (HR: 1.15; 95% CI: 0.80–1.66; p: 0.44; HR: 0.85; 95% CI: 0.48–1.54; p: 0.59 and HR: 1.35; 95% CI: 0.56–3.27; p: 0.50, respectively), but was responsible for increased VD risks, irrespective of cardiovascular risk factors or history of coronary events, stroke, or heart failure [83]. Further research is required to investigate the mechanisms linking beta(β)-blockers to a higher VD risk. In a recent study, various subgroups of antihypertensive medication (AHM), including β-blockers, were associated with lower dementia risk in primary care patients [84]. Moreover, the permeability of β-blockers towards the BBB exerted neuroprotective activity by removing toxic aggregates through the glymphatic system [85]. Table 4 summarizes the results of the studies discussed above. In short, no results supported the connection between an anticholinergic mechanism and an increased risk of dementia. Insufficient data could not confirm a causal mechanism for these drug categories. Nonetheless, in some cases, the advantages of anticholinergics may outweigh the disadvantages of specific clinical syndromes, supporting their suitable use for the elderly. 2.3. Benzodiazepine Drugs Benzodiazepines (BZDs) are CNS depressants that bind to gamma (γ)-aminobutyric acid-A (GABA-A) receptors. These drugs increase the effect of GABA, resulting in sedative, anticonvulsant, anxiolytic, and muscle relaxant effects. Hence, they reduce the brain’s sensitivity to stimulation, leading to a calming effect. They were primarily utilized to address anxiety, insomnia, and seizures. The side effects of these medications include drowsiness, unsteadiness, and confusion. The most commonly prescribed drugs in this category include alprazolam, diazepam, clonazepam, and lorazepam (Figure 6). Association of BZDs with Dementia and AD Risk There has been a notable rise in AD and dementia risk among older individuals using BZDs with extended half-lives and for a prolonged period [86,87,88,89,90,91,92]. Additionally, AD patients prescribed with BZDs had a 41% increased risk of mortality [93] and a 50% increased risk of AD [91] in comparison to those who did not take these medications. Likewise, patients on hypnotic drugs had a 21% higher chance of developing dementia than those who do not use them (OR: 1.21, 95% CI: 1.13–1.29; p < 0.001) [94]. The combined results from a meta-analysis indicated a notable link between taking BZDs and the likelihood of developing dementia (OR: 1.38, 95% CI: 1.07–1.77). Moreover, no variation in the risk of dementia between individuals using short-acting and long-acting BZDs (RR: 1.09 vs. 1.24) was observed [95]. On the other hand, another study reported a higher risk of dementia in individuals using long-acting BZDs (OR: 1.21, 95% CI: 0.99–1.49) in comparison to those using short-acting BZDs (OR: 1.13, 95% CI: 1.02–1.26) [96]. There is a possibility that BZDs impact cognition and may raise the chance of AD by affecting hippocampal α5GABAA receptors [97]. Zhong and colleagues examined how long-term use of BZDs was linked to dementia by conducting a meta-analysis with 45,391 participants and 1891 cases of dementia. A possible link between an increase in BZD dose and a 22% higher risk of developing dementia (Risk ratio [RR]:1:22, 95% CI: 1.18–1.25) was reported in the study [98]. Mura et al. [99] observed that long-term BZD usage was linked to worse cognitive function, but was not associated with faster cognitive deterioration in older age. Pietrzak et al. [100] observed that elders with anxiety could be at a heightened risk of developing AD, which may lead to elevated levels of Aβ in individuals with MCI and AD. There was a significant increase in the risk of MCI among APOEe4 carriers (HR 1.30; 95% CI 1.14—1.50) [101]. However, some other studies disapprove of any correlation between BZD use and AD or cognitive loss [6,102,103,104,105]. Wu et al. found weak evidence to conclude any correlation between BZD use and dementia in an umbrella review comprising five meta-analyses and 30 observational studies [105]. The strength of evidence was weak. BZD use in patients did not show a link to dementia, with Adjusted risk ratios of 1.06 (95% CI: 1.02–1.10), 1.05 (95% CI: 1.01–1.09), and 1.05 (95% CI: 1.02–1.09) for low, medium, and high users of benzodiazepines [106]. Extended use of BZDs over 2 years was linked to higher chances of being diagnosed with dementia, yet the findings lack statistical significance at the 5% or 10% thresholds (1.190; 95% CI: 0.925–1.531 and 1.167; 95% CI: 0.919–1.483) [8]. As individuals grow older, the likelihood of sleep disorders rises, which can impact the brain’s ability to remove toxic substances like Aβ [107]. Hence, it can be suggested that BZDs might indirectly have a protective impact on preventing AD by enhancing sleep quality [108]. Moreover, BZDs protect against glutamate excitotoxicity in AD [109]. Table 5 summarizes the results of the studies discussed above. The data compiled in this review do not warranty increased dementia/AD risk with BZD use. The use of BZDs had both advantages and disadvantages. Healthcare providers need to be aware of the dangers of long-term benzodiazepine use, such as dependence, withdrawal, and cognitive impairment, to promote safe and effective medication use. The injudicious use of medication can be prevented by alternate medications such as cognitive behavioral therapy for insomnia (CBT-i); the use of melatonin could also be a safer choice as medication, but further evidence would be needed to evaluate its long-term effect on health. Treating anxiety in elderly patients may be better addressed using alternative medications such as serotonin uptake inhibitors like sertraline or other compounds. 2.4. Proton Pump Inhibitors (PPIs) PPIs rank high among the drugs that are frequently prescribed on a global scale with an expected expenditure of USD 9 billion worldwide [111]. These medications inhibit the hydrogen-potassium adenosine triphosphatase enzyme (H+/K+ ATPase; Proton pump) present in the cells lining the stomach that produce acid. They are mainly used to treat stomach/duodenal ulcers and gastroesophageal reflux disease (GERD), as they assist in healing ulcers and reducing acid reflux by reducing gastric acid production. Some of the commonly prescribed PPIs include omeprazole, lansoprazole, rabeprazole, and pantoprazole (Figure 7). Although they work well for treating specific gastrointestinal problems, the potential risks require close supervision and evaluation of discontinuation methods to guarantee the best health results for the elderly. Therefore, it is advised to regularly assess PPI treatment to confirm that the lowest effective dose is being utilized for symptom management. Extended use of PPIs can alter the gut bacteria equilibrium, leading to a higher chance of infection, particularly pneumonia and Clostridium difficile (CDI). They have also been associated with a risk of cardiovascular, liver, and kidney disease [112]. PPIs hinder the absorption of vitamins and minerals like vitamin B12, magnesium, calcium, and iron, causing bone fractures, hypomagnesemia, and megaloblastic and iron-deficiency anemia [110]. PPTs can cross the BBB [113], and have also been reported to block acetylcholine synthesis by Choline acetyltransferase (ChAT), thereby potentially disrupting neurotransmission [114]. Association of PPIs with Dementia and AD Risk In recent years, some studies proposed a possible link between PPI use and dementia risk [9,115,116,117]. A 51% increased risk of developing dementia was observed by Welu et al. [118] in war veterans. A significant increase in dementia risk was also observed in Asian [119] and German [120] populations. A two-fold increased risk of developing dementia by PPI users [117] raised safety concerns over the use of PPIs. The association between PPIs and dementia may be due to increased Aβ accumulation that is linked to dementia, or by PPI-induced malabsorption, leading to vitamin B12 deficiency. Considerably reduced levels of vitamin B12 were reported in dementia and AD patients in comparison to the healthy controls [121,122,123]. Acidification of lysosomes was important for activated microglia to degrade Aβ [124] and was seen as an important factor in AD pathogenesis. PPIs are lipophilic weak bases that can cross the BBB and block lysosomal vacuolar (V)-ATPase, inhibiting lysosomal acidification. Eventually, the de-acidification results in a decrease in Aβ breakdown, and an increase in Aβ accumulation. PPIs increase their uptake by disturbing tight junctions in the BBB, affecting spatial memory [125,126] (Figure 8). Some other studies [127,128,129,130] found no association between the risk of dementia or AD and the use of PPIs, including in individuals with significant long-term exposure [131]. An increased dosage of PPIs did not show a higher risk for either AD or non-AD dementias (OR: 1.20; 95% CI: 0.91–1.61 and OR: 0.95; 95% CI: 0.74–1.22, respectively) [132]. Another meta-analysis study including 642,305 participants found no significant link between PPI use and dementia (HR: 1.04; 95% CI: 0.92–1.15) [10]. No connection between PPI and dementia risk was seen in the extensive meta-analysis (HR: 0.98; 95% CI: 0.85–1.13) either [133]. A clinical trial also supported the above results, where no statistically significant association (OR: 1.20; 95% CI: 0.81–1.78) between dementia and PPI (pantoprazole, 40 mg) use was seen [134]. A comprehensive review published last year, including meta-analyses and experimental and observational studies, also found no strong link between PPI use and the onset of cognitive decline or dementia [135]. Table 6 summarizes the results of the studies discussed above. While looking for further conclusive proof, doctors need to prescribe PPIs by weighing the advantages against possible drawbacks. The legitimate use of PPI medications should not be denied due to worries about dementia risk. Increased awareness and following evidence-based recommendations are crucial for maximizing PPI treatment and minimizing associated risks. Regularly checking and carefully planning how to reduce PPI prescriptions are important for effective management. For those with suitable reasons for PPI treatment, it is important to always start with the smallest effective dose and avoid unnecessary long-term or continuous treatment in appropriate individuals. A gradual reduction in dosage may be suitable for individuals who no longer have symptoms, and/or need to discontinue the PPI. Regular monitoring of serum vitamin B12 is necessary, particularly in older patients on long-term PPI treatment. Using cyanocobalamin may enhance vitamin B12 levels in cases where discontinuing PPI therapy is not possible. 2.5. Statins Statins are utilized in the treatment of high cholesterol levels and the management of atherosclerotic cardiovascular disease (CVD). Statins inhibit the enzyme hydroxymethylglutaryl-CoA (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Statins reduce total cholesterol levels, low-density lipoprotein (LDL), and triglycerides (TGs). Examples of FDA-approved statins are atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, and pitavastatin (Figure 9). The side effects of statins include fatigue, myopathy, and hepatic injury [137]. Association of Statins with Dementia and AD Risk In 2012, the US FDA expressed worries over the negative cognitive impact of statins [138], after some studies indicated their effect on memory [136]. The decreased statin use following the negative publicity resulted in increased myocardial infarction and CVD mortality [139]. Later, several other studies found that statin use does not increase dementia or AD risk [140,141,142,143,144], but helps reduce them instead. Studies suggested the role of statins in decreasing proinflammatory markers and controlling microglial activation in NDs [145] and by modulating G protein-gated inwardly rectifying potassium (GIRK) channel function [146] in neurons. Jeong and coworkers [147] found that less persistent use of statins (<540 days) was associated with increased AD risk, while consistent use of statins decreased the risk of AD [Adjusted hazard ratio (aHR); 95% CI = 0.87 (0.80–0.95)]. A meta-analysis with 30 observational studies (n = 9,162,509) indicated that statin use was associated with reduced dementia risk (Risk ratio [RR]: 0.83; 95% CI: 0.79–0.87), AD (RR: 0.69; 95% CI: 0.60–0.80, p < 0.0001), and VD (RR: 0.93; 95% CI: 0.74–1.16, p = 0.54) [148]. No adverse effect of statins was observed in randomized clinical trials and observational studies constituting 1,404,459 participants [149]. During follow-up, individuals taking statins had a lower chance of developing dementia, or cognitive impairment without dementia [150], and AD [151]. Similar results were reported by a nationwide cohort study in Taiwan where statin use significantly lowered the dementia risk in the aging population [152]. The outcomes were alike for lipophilic and hydrophilic statins and were additionally more pronounced for potent statins than the less potent statins [153]. Statins may play a therapeutic role in preventing Aβ-induced toxicity and improving insulin signaling by activating AMP-activated protein kinase (AMPK) [154] and decreasing neuroinflammation [155]. Statin use was linked to a reduced risk of AD by 28%, VD by 18%, and unspecified dementia by 20% [156] (Figure 10). With the rise in life expectancy, it will be crucial to define precise guidelines for prescribing statin therapy to elderly individuals to promote a healthier aging society. It was noted that several factors must be considered when utilizing statin therapy in elderly patients, including multiple health conditions and the use of polymedications, which can impact the effectiveness and safety of treatment. Drug interactions frequently occur in patients who are taking several medications. Lovastatin, simvastatin, and atorvastatin, metabolized by cytochrome p450, may interact with drugs like diltiazem, verapamil, amiodarone, and azole antifungals. These interactions were common in patients with atherosclerotic cardiovascular disease (ASCVD). In the elderly, pravastatin and rosuvastatin were preferable due to their lower risk of drug interactions and improved safety record [157]. On the other hand, discontinuing the treatment led to a higher likelihood of cardiovascular issues and increased risk of death [158]. Table 7 summarizes some of the important results discussed above. 3. Methods A comprehensive search was done for the published scientific research available on various databases (PubMed, Google Scholar, and Web of Science) until September 2024. These included observational studies, randomized case–control studies, meta-analysis and systematic reviews, and clinical studies on medications associated with AD and dementia risk. The search terms used were “drugs” and “medication” with the filters “Alzheimer’s disease risk” and “dementia risk”. Exclusion criteria: articles not specifying AD, or dementia were excluded. Non-English literature was excluded. 4. Conclusions Several searches using various factors and databases were carried out to find a piece of concrete evidence between the use of several medications and increased risks of dementia or AD, yet the results were inconclusive. The conflicting results in research could be due to the variability in the study design (sample size, ethnicity, methodology); biological differences (pharmacokinetic, pharmacodynamic, multiple health conditions); and other cofounding variables (sociodemographic factors, polypharmacy, comorbidities). Moreover, the studies considered only prescription medicine; therefore, it was impossible to determine if patients took additional over-the-counter drugs (allergy medicine, motion sickness patches, cough syrups, muscle relaxants). Like other geriatric syndromes, the risk factors for cognitive impairment are complex and could vary among individuals. Cognitive impairment is largely influenced by biological factors such as age, gender, and genetics. Furthermore, cognitive health can be significantly affected by psychological factors like depression and anxiety. The databases were expected to be trustworthy, but the accuracy of the recorded information could be ambiguous at times. With this information and the possibility of confusion, it is extremely difficult to determine the specific amount of risk linked to any category or specific medication. In the elderly, polypharmacy might result in potential drug–drug interaction; therefore, the patients should be regularly evaluated for their medications and any negative effects, opting for single-drug therapy over fixed-dose combinations, selecting medications with confirmed effectiveness, and discontinuing drugs as early as feasible. Adjusting the dosage timing for elderly patients susceptible to nutrient deficiencies can also help lessen interactions and side effects caused by multiple medications used by this population. In 2019, the American Geriatrics Society (AGS) Beers Criteria advised against using drugs with potent anticholinergic properties in elderly individuals with dementia or cognitive decline [160]. Instead, medications with a lower ACB like SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin and norepinephrine reuptake inhibitors) were seen as safer options. Several other criteria limited the PPI usage for not more than 8 weeks in the elderly [159,161]. Other risk factors for cognitive decline need to be acknowledged and possibly addressed, along with a focus on non-pharmacological treatments. Hence, it is crucial to consider the pros and cons of every medication. The possibility exists that the danger of dementia could be significantly lower than the danger to one’s health of not using the medication as directed. Hence, individuals should refrain from discontinuing prescribed medications without consulting their doctor.